Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron PK in Pediatric NDO/OAB
NCT02211846Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2014
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of mirabegron in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB), sponsored by Astellas Pharma. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 2 more. Started Sep 2014; status: completed.
02
Drugs
mirabegron
03
Conditions
neurogenic detrusor overactivity (NDO)overactive bladder (OAB)
Beyond the preview
Go deeper on NCT02211846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02211846.